Data edition of
Residue An evidence-graded reference for peptide science

Cagrilintide dosage in clinical trials

What dose levels researchers actually tested, quoted from the trial registry and the published reports — so the numbers circulating online can be checked against their source.

Doses in published trials

Table 1. Dose arms of the principal published Cagrilintide trials, as reported in the cited paper.
TrialPopulationDose armsScheduleRef.
Phase 2 dose-findingOverweight or obesity without diabetes; n=706 on cagrilintide0.3, 0.6, 1.2, 2.4, 4.5 mg (range 0.3–4.5 mg); liraglutide 3.0 mg comparatorOnce weekly SC1
Phase 1bOverweight or obesity; n=960.16–4.5 mg with semaglutide 2.4 mgOnce weekly SC2
Phase 2 T2DType 2 diabetes; n=922.4 mg (+ semaglutide 2.4 mg as CagriSema)Once weekly SC, 32 weeks3
REDEFINE 1 & 2Overweight or obesity, with and without T2D2.4 mg + semaglutide 2.4 mgOnce weekly SC, 68 weeks4,5
Figure 1. Dose levels named in ClinicalTrials.gov arm descriptions that mention Cagrilintide, counted once per study (7 interventional studies). Includes titration steps and single-dose pharmacology studies; a level appearing often is not evidence that it is effective or safe.

Arms as registered

Verbatim arm text from ClinicalTrials.gov. Only arms naming Cagrilintide and a dose are shown.

  1. NCT06131437 · Phase 3 · Completed · n=809

    A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

    • CagriSema 2.4 mg/2.4 mg — Participants will receive 2.4 mg cagrilintide and 2.4 mg semaglutide subcutaneously once-weekly (dose escalation period of 16 weeks) for up to 84 weeks.

  2. NCT05996848 · Phase 3 · Completed · n=300

    A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight

    • CagriSema — Participants will receive once-weekly subcutaneous (s.c) injections of 2.4 mg cagrilintide and 2.4 mg semaglutide for 44 weeks.

  3. NCT05813925 · Phase 3 · Completed · n=331

    A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight

    • CagriSema 2.4 mg/2.4 mg — Participants will receive 2.4 milligrams (mg) cagrilintide and 2.4 mg semaglutide subcutaneously (s.c.) once-weekly (OW) after a dose escalation period of 16 weeks (0.25 mg of cagrilintide and 0.25 mg of semaglutide from weeks 0-4, 0.5 mg of cagrilintide and 0.5 mg of semaglutide from weeks 5-8, 1 mg of cagrilintide and 1 mg of semaglutide from weeks 9-12 and 1.7 mg of cagrilintide and 1.7 mg of semaglutide from weeks 13-16) during the maintenance period for 52 weeks

  4. NCT04982575 · Phase 2 · Completed · n=92

    Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes

    • Cagrilintide 2.4 mg and semaglutide 2.4 mg — Participants will receive cagrilintide and semaglutide once a week as injections for 32 weeks.
    • Cagrilintide 2.4 mg and placebo (semaglutide) — Participants will receive cagrilintide and placebo (semaglutide) once a week as injections for 32 weeks
    • Semaglutide 2.4 mg and Placebo (cagrilintide) — Participants will receive semaglutide and placebo (cagrilintide) once a week as injections for 32 weeks

  5. NCT05804162 · Phase 1 · Completed · n=107

    A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants

    • Cagrilintide (Arm 1) — Participants will receive 0.6 milligrams (mg) of cagrilintide subcutaneously once weekly and the dose will be then escalated once in 2 weeks for 8 weeks until the target maintenance dose of 4.5 mg is reached followed by a 38-day post-treatment period. In addition, a single dose of moxifloxacin placebo prior to initiation of treatment and a single dose moxifloxacin placebo at the end of the treatment period will be administered orally.

  6. NCT05564104 · Phase 1 · Completed · n=32

    A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body

    • Part A: Participants with normal hepatic function — Participants with normal hepatic function will receive a single subcutaneous (s.c.) dose of 0.9 milligrams (mg) of cagrilintide on Day 1.
    • Part A: Participants with mild hepatic impairment — Participants with mild hepatic impairment (Child Pugh Grade A) will receive a single subcutaneous (s.c.) dose of 0.9 milligrams (mg) of cagrilintide on Day 1.
    • Part A: Participants with moderate hepatic impairment — Participants with moderate hepatic impairment (Child-Pugh Grade B) will receive a single subcutaneous (s.c.) dose of 0.9 milligrams (mg) of cagrilintide on Day 1.
    • Part A: Participants with severe hepatic impairment — Participants with severe hepatic impairment (Child-Pugh Grade C) will receive a single subcutaneous (s.c.) dose of 0.9 milligrams (mg) of cagrilintide on Day 1.

  7. NCT04940078 · Phase 1 · Completed · n=40

    A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity

    • Part A: Cagrilintide and semaglutide in separate syringes — Participants will up-titrated for 14 weeks (dose escalation every 4 weeks and 2 weeks at last dose escalation step prior to randomisation) with cagrilintide and semaglutide administered as separate injections. Followed by 8 weeks treatment with cagrilintide and semaglutide administered as separate injections. The 8-week treatment period covers 2 different doses of cagrilintide and semaglutide (1.7/1.7 mg and 2.4/2.4 mg with 4 weeks on each dose combination). Followed by a 38 days follow-up period.
    • Part A: Cagrilintide and semaglutide combined in DV3384 device — Participants will be up-titrated for 14 weeks (dose escalation every 4 weeks and 2 weeks at last dose escalation step prior to randomisation) with cagrilintide and semaglutide administered as separate injections. Followed by 8 weeks of treatment with cagrilintide and semaglutide administered using the DV3384 manual syringe. The 8-week treatment period covers 2 different doses of cagrilintide and semaglutide (1.7/1.7 mg and 2.4/2.4 mg with 4 weeks on each dose combination. Followed by a 38 days follow-up period.
    • Part B: Cagrilintide and semaglutide combined in DV3384 device — Participants will receive a single injection of Cagrilintide 0.25 mg/semaglutide 0.25 mg using the DV3384 manual syringe followed by a 28 days follow-up period.

References

Every source below was retrieved from its official API or page and cached on the data-edition date. Numbers match the margin notes.

  1. 1 PubMed Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet 2021. PMID 34798060; doi:10.1016/S0140-6736(21)01751-7.
  2. 2 PubMed Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet 2021. PMID 33894838; doi:10.1016/S0140-6736(21)00845-X.
  3. 3 PubMed Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet 2023. PMID 37364590; doi:10.1016/S0140-6736(23)01163-7.
  4. 4 PubMed Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2025. PMID 40544433; doi:10.1056/NEJMoa2502081.
  5. 5 PubMed Davies MJ, Bajaj HS, Broholm C, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med 2025. PMID 40544432; doi:10.1056/NEJMoa2502082.

← Cagrilintide monograph · Why we publish trial doses